ATX
Amplia Therapeutics Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 7.92%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
📈 Performance
Price History
-41.05%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.10
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ATX
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in ATX
N/A
ATX investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in ATX also invest in...
Want more shares? Try these...
The Agency Group Australia Ltd. engages in providing real estate and financial services. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-12-18. The Company’s principal activity consists of real estate services and related activities. The company segments include Real Estate Property Services and Mortgage Origination Services. Its Real Estate and Property Services segment is engaged in the provision of real estate services including selling of property, settlement agent services, and property management. Its Mortgage Origination Services segment is engaged in the provision of mortgage broking services. The firm's wholly owned subsidiaries include Agency Partners WA Pty Ltd, Ausnet Financial Planning Services Pty Ltd, Ausnet Financial Pty Ltd, Ausnet Property Investment Fund Pty Ltd, Ausnet Real Estate Services Pty Ltd, Bushby & Co. Pty Ltd, Jelina Holdings Pty Ltd, Move Property Solutions Pty Ltd, The Agency Auctions NSW Pty Ltd, The Agency Canberra Pty Ltd, The Agency Commercial Real Estate Pty Ltd, and The Agency Marketing Pty Ltd.
🙌 Performance (5Yr p.a)
-13.33%
📊 Share price
$0.02 AUD
🏠 REAL ESTATE
Audeara Ltd. engages in the development of noise-cancelling consumer headphones. The company is headquartered in Fortitude Valley, Queensland. The company went IPO on 2021-05-18. The firm specializes in listening solutions for people with hearing challenges. Its principal activity is development of hearing health technology. Its headphones deliver personalized audio to users via Bluetooth headphones. Its headphones are categorized as an assistive listening device (ALD), which can be paired with its mobile application called the Audeara App. Its technology is compatible for use with cochlear implants and hearing aids. The Audeara App uses a personalized algorithm to calibrate the headphones for an individual’s hearing profile. This provides clear sound quality for video conferencing and telephone calls and using mainstream applications like watching television, listening to music, and gaming. Its products include A-01 Headphones, BT-01 Transceiver, A-02 Headphones and A-02 TV Bundle. The company sells its products through distributors and resellers in Australia and North America, and via e-commerce channels.
📊 Share price
$0.05 AUD
🛍️ CONSUMER
